Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?
about
Applications of CYP450 testing in the clinical settingTreatment of Helicobacter pylori infection: Current and future insightsClopidogrel and proton pump inhibitors--where do we stand in 2012?CYP2C19 polymorphism influences Helicobacter pylori eradicationThe First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.Drug-drug interaction between clopidogrel and the proton pump inhibitors.Clinical evidence of interaction between clopidogrel and proton pump inhibitorsIn Vitro Evaluation of Nasogastric Tube Delivery Performance of Esomeprazole Magnesium Delayed-Release Capsules.Antiplatelet agents and proton pump inhibitors - personalizing treatment.Comparison of esomeprazole enteric-coated capsules vs esomeprazole magnesium in the treatment of active duodenal ulcer: a randomized, double-blind, controlled studyCYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.Acid peptic diseases: pharmacological approach to treatment.Pharmaceutical principles of acid inhibitors: unmet needs.Rabeprazole for the treatment of acid-related disorders.The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment.Effects of bile acids on human airway epithelial cells: implications for aerodigestive diseases.Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.Proton pump inhibitors and the risk of severe cognitive impairment: The role of posttraumatic stress disorder.Systemic administration of omeprazole interferes with bone healing and implant osseointegration: an in vivo study on rat tibiae.Hypersensitivity Reactions to Proton Pump Inhibitors
P2860
Q24621760-9DE1DBFA-0E27-46A4-A363-1B4FEE85E8E2Q26769707-D1C6FD86-DD55-489E-8A2D-FDD326DB549AQ26825728-BB380892-FB06-4D40-AB3A-9FC67E37D163Q27005916-78CC9274-1C4A-4B6F-B242-A5130197550BQ34494081-E95A8A90-FF19-40FD-9470-AB0E5483E75DQ34983154-701A7968-3E95-4F2F-89E5-2CA2DC534DD1Q35033722-89CF684F-EC5C-402B-B6C9-18E07877D63BQ36349085-FA007535-B733-42F3-9C10-BA880818A2F0Q36441481-150D872E-2C2C-403F-8F88-6BACEF8B17C0Q37237706-DE46D10D-A964-4A91-A242-F820B9F9A4E9Q37646785-5E913F29-6A47-41D1-A1D0-E5CEE8E2D6CAQ37799470-020E56BC-C9D0-443E-90FA-5AF04B46F3C8Q37913063-772C36E0-1628-4D70-B78D-E2B60FBF6D0BQ37957701-C653D41B-9BBF-492E-B25C-94D3B7EDA51EQ38038691-857BFC8C-009C-4E80-9AEC-9920D29D8081Q38117182-E371E928-CFA3-4E7E-9A1D-553752F5DECDQ38710446-83621A9B-0311-48FF-A5EF-5C8960B24ABFQ38861693-5B99967D-C3AB-4060-A0DE-C489F15A977DQ38865456-D2C2302A-C1F9-40DF-8D3D-55B59EE54140Q45019665-9069824B-CBF6-4C15-9013-9A8BA450CFCBQ46203790-217DB61C-37DB-4401-9A80-FDD0D15FFAC7Q47221042-E54FA8E7-3071-4DCF-9A73-EEFAB662C704Q51578494-BEAE00F4-935F-46FD-A9DB-026E5836A4FAQ56431956-06034407-896A-459C-AC6C-52C791CC9448
P2860
Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Proton pump inhibitors: do dif ...... ferences in clinical outcomes?
@en
Proton pump inhibitors: do dif ...... ferences in clinical outcomes?
@nl
type
label
Proton pump inhibitors: do dif ...... ferences in clinical outcomes?
@en
Proton pump inhibitors: do dif ...... ferences in clinical outcomes?
@nl
prefLabel
Proton pump inhibitors: do dif ...... ferences in clinical outcomes?
@en
Proton pump inhibitors: do dif ...... ferences in clinical outcomes?
@nl
P2093
P1476
Proton pump inhibitors: do dif ...... ferences in clinical outcomes?
@en
P2093
Edmund Jon Deon Lee
Kwong Ming Fock
Lean Choo Bee
P356
10.2165/00003088-200847010-00001
P577
2008-01-01T00:00:00Z
P6179
1044509371